USE OF DIPYRIDAMOLE IN COMBINATION WITH ACETYLSALICYLIC ACID AND AN ANGIOTENSIN II ANTAGONIST FOR STROKE PREVENTION

(19)

(11)

EP 1 603 573 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.04.2009 Bulletin 2009/14

(45)	Mention of the grant of the patent:
	21.05.2008 Bulletin 2008/21

(21)	Application number: 04709596.3

(22)	Date of filing: 10.02.2004

(51)

International Patent Classification (IPC):

A61K 31/60^(2006.01)
A61K 31/4184^(2006.01)

A61K 31/519^(2006.01)
A61P 9/00^(2006.01)

(86)	International application number:
	PCT/EP2004/001208

(87)	International publication number:
	WO 2004/071385 (26.08.2004 Gazette 2004/35)

(54)

USE OF DIPYRIDAMOLE IN COMBINATION WITH ACETYLSALICYLIC ACID AND AN ANGIOTENSIN II ANTAGONIST FOR STROKE PREVENTION

KOMBINATIONSPRÄPARATE ZUR VERHINDERUNG VON SCHLAGANFÄLLEN, WELCHE DIPYRIDAMOLE, ACETYLSALICYLSÄURE UND EINEN ATII ANTAGONISTEN ENTHALTEN

UTILISATION DE DIPYRIDAMOLE EN ASSOCIATION AVEC DE L'ACIDE ACETYLSALICYLIQUE ET UN ANTAGONISTE DE L'ANGIOTENSINE II AUX FINS DE LA PREVENTION DES ACCIDENTS CEREBRO-VASCULAIRES

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
	Designated Extension States:
	LT LV

(30)

Priority:

13.02.2003 DE 10306179
08.08.2003 EP 03018212

(43)	Date of publication of application:
	14.12.2005 Bulletin 2005/50

(60)	Divisional application:
	06121998.6 / 1733729

(73)	Proprietors:
	Boehringer Ingelheim International GmbH 55216 Ingelheim am Rhein (DE) Designated Contracting States: AT BE BG CH CY CZ DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR Boehringer Ingelheim Pharma GmbH & Co.KG 55216 Ingelheim am Rhein (DE) Designated Contracting States: DE

(72)	Inventors:
	HILBRICH, Lutz 55252 Mainz-Kastel (DE) GILBERT, James C. Bethlehem, Connecticut 06751 (US) HUMPHREYS,David, Michael I-52031 Anghiari (IT) RIEDEL, Axel Maselheim D-88437 (DE)

(56)

References cited: :

WO-A-01/15673

WO-A-01/30353

"AGGRENOX: A COMBINATION OF ANTIPLATELET DRUGS FOR STROKE PREVENTION" MEDICAL LETTER ON DRUGS AND THERAPEUTICS, NEW ROCHELLE, NY, US, vol. 42, no. 1071, 7 February 2000 (2000-02-07), pages 11-12, XP000933411 ISSN: 0025-732X
SCHEEN A J: "LA COMBINAISON FIXE DIPYRIDAMOLE - ACIDE ACETYLSALICYLIQUE (AGGRENOX) EXTENDED-RELEASE DIPYRIDAMOLE/ASPIRIN (AGGRENOXÄRHOÜ" REVUE MEDICALE DE LIEGE, LIEGE, BE, vol. 55, no. 10, 2000, pages 957-959, XP009033957 ISSN: 0370-629X
MALININ A I ET AL: "AGGRENOX (EXTENDED-RELEASE DIPYRIDAMOLE AND LOW-DOSE ASPIRIN IN COMBINATION): PROTECTING PLATELETS FROM EXCESSIVE ACTIVATION IN PATIENTS WITH VASCULAR EVENTS" HEART DRUG, KARGER, BASEL, CH, vol. 2, no. 2, March 2002 (2002-03), pages 93-104, XP009033969 ISSN: 1422-9528
BOEHRINGER INGELHEIM NEWS, [Online] XP002297102 13-02-2003 Retrieved from the Internet: URL:http://www.boehringer-ingelheim.com/co rporate/asp/archive/adetail.asp?ID=594> [retrieved on 2004-09-20]


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).